Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of inhaled Treprostinil Liposome (L606) in pulmonary hypertension associated with interstitial lung disease
2024-517943-29-00Phase 3Authorised
- Sponsor
- Liquidia Corporation
- Start
- Apr 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD) comparing Treprostinil Liposome inhalation with Placebo inhalation (2 arms). Primary endpoint: Change from Baseline to Week 16 in 6-minute walk distance. Planned start Apr 2026; status: authorised.
02
Drugs
treprostinil liposome
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on 2024-517943-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517943-29-00.